Gocatamig clinical trials
Gocatamig is named as an intervention in 3 current clinical trials in our USA, China, Spain, Turkey, South Korea, Israel, UK, Japan, Taiwan, Australia, Germany, Italy and Poland registers. 2 are recruiting patients now. All registered phases are Phase 1/2. The sponsor with the most trials is Merck Sharp & Dohme LLC (2). The most-studied condition is Small Cell Lung Cancer.
How Gocatamig works
All drug targets →- CancerPhase 1/2
- Small cell lung carcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068123, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Gocatamig
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Gocatamig
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137 · Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | Merck Sharp & Dohme LLC | UK, USA, China, Spain, Turkey, Japan, South Korea, Taiwan, Australia, Israel |
|
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597 · Small Cell Lung Cancer Extensive Stage
|
Phase 1/2 | Recruiting | Merck Sharp & Dohme LLC | USA, China, Germany, Spain, Italy, Poland, Turkey, South Korea, Israel |
|
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT04471727 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
|
Phase 1/2 | Active, closed | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Gocatamig
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 2 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Gocatamig trials
How many clinical trials are testing Gocatamig?
3 current trials in our USA, China, Spain, Turkey, South Korea, Israel, UK, Japan, Taiwan, Australia, Germany, Italy and Poland registers name Gocatamig (also registered as HPN328) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Gocatamig trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in China, 2 with sites in Spain, 2 with sites in Turkey, 2 with sites in South Korea, 2 with sites in Israel, 1 with sites in UK, 1 with sites in Japan, 1 with sites in Taiwan, 1 with sites in Australia, 1 with sites in Germany, 1 with sites in Italy and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Gocatamig clinical trials?
Merck Sharp & Dohme LLC (2) and Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gocatamig works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gocatamig works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gocatamig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.